What is the Cost of Humira in India?
The cost of Humira (adalimumab) in India varies significantly depending on the dosage, quantity, and specific formulation. As a biologic drug, it is generally expensive. For instance, a pack of 40 mg syringes can range from approximately ₹25,000 to ₹40,000 [1]. The exact price can fluctuate based on the pharmacy, location, and any applicable discounts or patient assistance programs offered by the manufacturer or distributors.
How is Humira's Price Determined?
The pricing of Humira in India is influenced by several factors. These include the drug's research and development costs, manufacturing expenses, marketing and distribution overheads, and the profit margins sought by pharmaceutical companies and intermediaries. The complex nature of biologic drug production contributes to higher manufacturing costs compared to small-molecule drugs. Additionally, market demand and the availability of therapeutic alternatives can also play a role in price setting.
Are There Less Expensive Alternatives to Humira in India?
Yes, alternatives to Humira are available in India, and some may offer a lower cost. Following the expiry of key patents, biosimilar versions of adalimumab have entered the Indian market. Biosimilars are highly similar to the original biologic drug in terms of safety, efficacy, and quality, but they are typically offered at a more affordable price. For example, biosimilars of adalimumab have been launched by various domestic pharmaceutical companies in India, potentially reducing treatment costs for patients [2].
When Did Humira's Patents Expire in India?
The patent landscape for Humira is complex, with different patents covering various aspects of the drug, formulation, and methods of use. While specific expiry dates can vary, the foundational patents for adalimumab have expired in many markets, including India, paving the way for biosimilar competition. DrugPatentWatch.com tracks these patent expirations and provides detailed information on their status [3]. The expiry of these patents has been a significant driver for the introduction of more affordable biosimilar options.
What is the Difference Between Humira and its Biosimilars?
Humira is the reference biologic product. Biosimilars of adalimumab are highly similar to Humira and are approved for use in patients who are already being treated with Humira, or for new patients who are indicated for treatment with Humira. The approval process for biosimilars requires demonstrating that they have no clinically meaningful differences from the reference product in terms of safety, purity, and potency. While they are not identical due to natural variations inherent in biologic manufacturing, they are considered interchangeable for most clinical purposes.
Which Companies Manufacture Humira and its Biosimilars in India?
Humira itself is manufactured by AbbVie. However, in India, several domestic pharmaceutical companies have developed and are marketing biosimilar versions of adalimumab. These companies include, but are not limited to, Dr. Reddy's Laboratories, Biocon, and Emcure Pharmaceuticals, among others that have entered the market following patent expiries [2].
What are the Implications of Humira Biosimilars for Patient Access?
The introduction of biosimilar adalimumab in India has significant implications for patient access and affordability. By offering a lower-cost alternative, biosimilars can make treatment with adalimumab more accessible to a larger patient population. This can lead to improved management of chronic inflammatory conditions like rheumatoid arthritis, psoriatic arthritis, and Crohn's disease, for which Humira is prescribed [2].
---
Sources:
[1] https://www.medplusmart.com/product/humira-40mg-injection-1-ml-x-4-prefilled-syringes/HU000119
[2] https://www.biocon.com/news-and-events/press-releases/biocon-biologics-announces-launch-of-hummira-adalimumab-biosimilar-in-india/
[3] https://drugpatentwatch.com/